These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28134398)

  • 1. [New biomarkers of CKD-MBD].
    Pasquali M; Tartaglione L; Rotondi S
    G Ital Nefrol; 2016; 33(6):. PubMed ID: 28134398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management?
    Tan SJ; Cai MM
    Nephrology (Carlton); 2017 Mar; 22 Suppl 2():14-18. PubMed ID: 28429560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin: a new biomarker of CKD-MBD.
    Figurek A; Rroji M; Spasovski G
    Int Urol Nephrol; 2020 Jan; 52(1):107-113. PubMed ID: 31612420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.
    Graciolli FG; Neves KR; Barreto F; Barreto DV; Dos Reis LM; Canziani ME; Sabbagh Y; Carvalho AB; Jorgetti V; Elias RM; Schiavi S; Moysés RMA
    Kidney Int; 2017 Jun; 91(6):1436-1446. PubMed ID: 28318623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A; Spasovski G
    Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineral metabolism and cardiovascular disease in CKD.
    Fujii H; Joki N
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Klotho-FGF23, Cardiovascular Disease, and Vascular Calcification: Black or White?
    Cianciolo G; Galassi A; Capelli I; Schillaci R; La Manna G; Cozzolino M
    Curr Vasc Pharmacol; 2018 Jan; 16(2):143-156. PubMed ID: 28294047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?
    Evenepoel P; Rodriguez M; Ketteler M
    Semin Nephrol; 2014 Mar; 34(2):151-63. PubMed ID: 24780470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Klotho/FGF23 Axis in CKD.
    Tsuchiya K; Nagano N; Nitta K
    Contrib Nephrol; 2015; 185():56-65. PubMed ID: 26023015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Klotho, a Potential Biomarker of Chronic Kidney Disease-Mineral Bone Disorders Involved in Healthy Ageing: Lights and Shadows.
    Martín-Vírgala J; Martín-Carro B; Fernández-Villabrille S; Ruiz-Torres MP; Gómez-Alonso C; Rodríguez-García M; Fernández-Martín JL; Alonso-Montes C; Panizo S; Cannata-Andía JB; Naves-Díaz M; Carrillo-López N
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and Urinary Soluble α-Klotho as Markers of Kidney and Vascular Impairment.
    Martín-Vírgala J; Fernández-Villabrille S; Martín-Carro B; Tamargo-Gómez I; Navarro-González JF; Mora-Fernández C; Calleros L; Astudillo-Cortés E; Avello-Llano N; Mariño G; Dusso AS; Alonso-Montes C; Panizo S; Cannata-Andía JB; Naves-Díaz M; Carrillo-López N
    Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FGF23 and Klotho system beyond mineral metabolism.
    Kuro-O M
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):64-69. PubMed ID: 27838783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels.
    Torino C; Pizzini P; Cutrupi S; Tripepi G; Mallamaci F; Thadhani R; Zoccali C
    Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):260-266. PubMed ID: 28017524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Kidney Disease-Mineral Bone Disease Biomarkers in Kidney Transplant Patients.
    Hasparyk UG; Vigil FMB; Bartolomei VS; Nunes VM; Simões E Silva AC
    Curr Med Chem; 2022 Aug; 29(31):5230-5253. PubMed ID: 35306980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. News on biomarkers in CKD-MBD.
    Mazzaferro S; Tartaglione L; Rotondi S; Bover J; Goldsmith D; Pasquali M
    Semin Nephrol; 2014 Nov; 34(6):598-611. PubMed ID: 25498379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fucoidan Ameliorates Renal Injury-Related Calcium-Phosphorus Metabolic Disorder and Bone Abnormality in the CKD-MBD Model Rats by Targeting FGF23-Klotho Signaling Axis.
    Liu BH; Chong FL; Yuan CC; Liu YL; Yang HM; Wang WW; Fang QJ; Wu W; Wang MZ; Tu Y; Wan ZY; Wan YG; Wu GW
    Front Pharmacol; 2020; 11():586725. PubMed ID: 33708111
    [No Abstract]   [Full Text] [Related]  

  • 20. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!
    Brandenburg VM; Verhulst A; Babler A; D'Haese PC; Evenepoel P; Kaesler N
    Nephrol Dial Transplant; 2019 Mar; 34(3):408-414. PubMed ID: 29846712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.